SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ELUT

Elutia Inc. (NASDAQ:ELUT)

US · Delayed Price · Currency is USD
Also listed: AZYOHealthcare · Biotechnology
$0.90+$0.09 (+11.12%)
 
Market cap
$39.9M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 7, 2020
Website
Market Cap$39.86M+52.5%
Revenue (ttm)$9.95M-52.8%
Net Income$54.39M+305.5%
EPS$1.10+219.7%
Shares Out44.29M
PE Ratio0.70
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume83,279
Open$0.79
Previous Close$0.81
Day's Range$0.79 - $0.92
52-Week Range$0.50 - $1.39
Beta0.92
AnalystsBuy
Price Target$8.88(+886.56%)
Earnings DateMar 3, 2027
+12.35% (1D)
No price history available.

About ELUT

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Address
20 Firstfield Road, Gaithersburg, MD, 20878, US
Market Cap
40 million
Employees
26
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$160.71K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From ELUT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+11.12%
5 Days
+9.93%
1 Month
+9.39%
6 Months
-24.99%
1 Year
+52.53%

$ELUT stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ELUT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ELUT's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ELUT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ELUT Revenue by Segment

$1.29MTotal
Summary of items regularly provided to the CODM$1.14M88.28%
Litigation costs, net$117.00K9.08%
Stock-based compensation$34.00K2.64%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ELUT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ELUT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ELUT

VTIVanguard Morningstar Total Stock Market ETF$593.65K
VXFVanguard Extended Market ETF$221.53K
IWCiShares Micro-Cap ETF$86.13K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ELUT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
63.76
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
7
Sells
0
Buy Value
$160.71K
Distinct Buyers
5

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.